HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic diseases - HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic diseases

Hematology, Osaka City University, Graduate School of Medicine0 sites17 target enrollmentJune 12, 2009

Overview

Phase: 未知
Intervention: Not specified
Conditions: Acute myeloid leukemia(AML) Acute lymphoblastic leukemia (ALL) Secondary acute myelogenous leukemia Chronic myeloid leukemia (CML) Myelodysplastic syndrome (MDS)
Sponsor: Hematology, Osaka City University, Graduate School of Medicine
Enrollment: 17
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

June 12, 2009

End Date

February 28, 2015

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Hematology, Osaka City University, Graduate School of Medicine

•1\) Major organ dysfunction a) Total bilirubin: \>\= 2\.0mg/dl b) Serum creatinine: \>\= 2\.0mg/dl c) Ejection fraction: \< 50 % d) Pulmonary function test: %VC \<40%, FEV1\.0% \<50% or SaO2 \<90% on room air e) AST or ALT \>\= 3 x UNL 2\) Uncontrolled active infection 3\) Uncontrolled CNS invasion 4\) Poorly controlled insulin\-treated diabetes mellitus 5\) Poorly controlled hypertension 6\) Patients with a severe complication including heart failure, coronary failure, acute myocardial infarction within the last 3 months, liver cirrhosis and interstitial pneumonia 7\) Pregnant, nursing or possible fertile woman 8\) Patients with severe mental disorder who are likely to unable to participate in the study 9\) A history of hypersensitivity or allergy to any drugs in conditioning regimen of this transplant 10\) HIV antibody positivity 11\) No indication for this study judged by physician in charge. (Note: HBs antigen positivity and HCV antibody positivity is not excluded.)